Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Cervical Cancer

  Free Subscription

Articles published in Radiother Oncol

Retrieve available abstracts of 28 articles:
HTML format

Single Articles

    September 2022
  1. SKIPAR K, Hompland T, Vassmo Lund K, Londalen A, et al
    Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer.
    Radiother Oncol. 2022 Sep 13. pii: S0167-8140(22)04266.
    PubMed     Abstract available

    July 2022
  2. DANKULCHAI P, Harn-Utairasmee P, Prasartseree T, Nakkasae P, et al
    Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy.
    Radiother Oncol. 2022 Jul 12. pii: S0167-8140(22)04205.
    PubMed     Abstract available

  3. DAVIDE C, Luca R, Benedetta G, Rosa A, et al
    Evaluation of early regression index as response predictor in cervical cancer: a retrospective study on T2 and DWI MR images.
    Radiother Oncol. 2022 Jul 7. pii: S0167-8140(22)04186.
    PubMed     Abstract available

    May 2022
  4. HANDE V, Chopra S, Kalra B, Abdel-Wahab M, et al
    Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis.
    Radiother Oncol. 2022;170:70-78.
    PubMed     Abstract available

    February 2022
  5. REIJTENBAGH DMW, Godart J, de Leeuw AAC, Seppenwoolde Y, et al
    Multi-center analysis of machine-learning predicted dose parameters in brachytherapy for cervical cancer.
    Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00107.
    PubMed     Abstract available

    January 2022
  6. WESTERVELD H, Kirchheiner K, Nout RA, Tanderup K, et al
    Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: an EMBRACE-I sub-study.
    Radiother Oncol. 2022 Jan 18. pii: S0167-8140(21)09082.
    PubMed     Abstract available

    December 2021
  7. MELL LK
    Trials and tribulations of bone marrow sparing radiotherapy for cervical cancer.
    Radiother Oncol. 2021 Dec 9. pii: S0167-8140(21)09021.

    October 2021
  8. ZHOU P, Zhang Y, Luo S, Zhang S, et al
    Pelvic bone marrow sparing radiotherapy for cervical cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08782.
    PubMed     Abstract available

  9. SRINIVASAN S, Gurram L, Johnny C, Chopra S, et al
    Validation and applicability of para-aortic lymph nodal contouring atlas in cervical cancer.
    Radiother Oncol. 2021 Oct 25. pii: S0167-8140(21)08781.
    PubMed     Abstract available

    September 2021
  10. CORBEAU A, Kuipers SC, de Boer SM, Horeweg N, et al
    Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
    Radiother Oncol. 2021 Sep 21. pii: S0167-8140(21)06732.
    PubMed     Abstract available

  11. PETERS M, de Leeuw AAC, Nomden CN, Tanderup K, et al
    Risk factors for nodal failure after radiochemotherapy and image-guided brachytherapy in locally advanced cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2021 Sep 1. pii: S0167-8140(21)06714.
    PubMed     Abstract available

    May 2021
  12. MAHANTSHETTY U, Poetter R, Beriwal S, Grover S, et al
    IBS-GEC ESTRO-ABS Recommendations for CT Based Contouring in Image Guided Adaptive Brachytherapy for Cervical cancer.
    Radiother Oncol. 2021 May 17. pii: S0167-8140(21)06248.
    PubMed     Abstract available

  13. YUCE SARI S, Yigit E, Gultekin M, Yildiz F, et al
    In regard to Spampinato et al.
    Radiother Oncol. 2021;158:321-322.

  14. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Response to Yuce Sari et al.
    Radiother Oncol. 2021;158:323-324.

    April 2021
  15. MOHAMMADI R, Shokatian I, Salehi M, Arabi H, et al
    Deep learning-based Auto-segmentation of Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.
    Radiother Oncol. 2021 Apr 5. pii: S0167-8140(21)06170.
    PubMed     Abstract available

    March 2021
  16. HUMPHREY P, Dures E, Hoskin P, Cramp F, et al
    Brachytherapy for locally advanced cervical cancer: a survey of UK provision of care and support.
    Radiother Oncol. 2021 Mar 16. pii: S0167-8140(21)06133.
    PubMed     Abstract available

    February 2021
  17. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2021 Feb 2. pii: S0167-8140(21)00020.
    PubMed     Abstract available

    January 2021
  18. PETRIC P, Lindegaard JC, Sturdza A, Fokdal L, et al
    Results of Image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study.
    Radiother Oncol. 2021 Jan 18. pii: S0167-8140(21)00005.
    PubMed     Abstract available

    October 2020
  19. CHOPRA S, Mangaj A, Sharma A, Tee Tan L, et al
    Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.
    Radiother Oncol. 2020 Oct 31. pii: S0167-8140(20)30884.
    PubMed     Abstract available

  20. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Importance of the ICRU Bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30839.
    PubMed     Abstract available

  21. RODRIGUEZ-LOPEZ JL, Ling DC, Keller A, Kim H, et al
    Ureteral Stenosis after 3D MRI-based Brachytherapy for Cervical Cancer - Have We Identified All the Risk Factors?
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30846.
    PubMed     Abstract available

  22. LIU Z, Liu X, Guan H, Zhen H, et al
    Development and Validation of a Deep Learning Algorithm for Auto-delineation of Clinical Target Volume and Organs at Risk in Cervical Cancer Radiotherapy.
    Radiother Oncol. 2020 Oct 8. pii: S0167-8140(20)30835.
    PubMed     Abstract available

  23. WATANABE Y, Nakamura S, Ichikawa Y, Ii N, et al
    Early Alteration in Apparent Diffusion Coefficient and Tumor Volume in Cervical Cancer Treated with Chemoradiotherapy or Radiotherapy: Incremental Prognostic Value over Pretreatment Assessments.
    Radiother Oncol. 2020 Oct 8. pii: S0167-8140(20)30834.
    PubMed     Abstract available

    June 2020
  24. DUKE SL, Tan LT, Jensen NBK, Rumpold T, et al
    Implementing an online radiotherapy quality assurance programme with supporting continuous medical education - report from the EMBRACE-II evaluation of cervix cancer IMRT contouring.
    Radiother Oncol. 2020;147:22-29.
    PubMed     Abstract available

    April 2020
  25. SPAMPINATO S, Tanderup K, Marinovskij E, Axelsen S, et al
    MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy.
    Radiother Oncol. 2020;145:117-124.
    PubMed     Abstract available

  26. SCHMID MP, Fokdal L, Westerveld H, Chargari C, et al
    Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer.
    Radiother Oncol. 2020;145:36-44.
    PubMed     Abstract available

    February 2020
  27. SWAMIDAS J, Kirisits C, De Brabandere M, Hellebust TP, et al
    Image registration, contour propagation and dose accumulation of external beam and brachytherapy in gynecological radiotherapy.
    Radiother Oncol. 2020;143:1-11.
    PubMed     Abstract available

  28. TRAVERSO A, Kazmierski M, Welch ML, Weiss J, et al
    Sensitivity of radiomic features to inter-observer variability and image pre-processing in Apparent Diffusion Coefficient (ADC) maps of cervix cancer patients.
    Radiother Oncol. 2020;143:88-94.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.